NYSE$ATR

AptarGroup Inc. · Q1 2024 earnings

Q1 2024 earnings · · Investor relations

Briefing

AptarGroup's Q1 2024 results were driven by growth in proprietary drug delivery systems, increased injectables sales, and an improving picture for consumer dispensing technologies in North America.

AptarGroup reported a strong first quarter with a 6% increase in reported sales and a 5% increase in core sales. Net income increased by 52% to $83 million, with reported earnings per share up 50% to $1.23 and adjusted earnings per share up 31% to $1.26.

  • Reported sales grew 6% and core sales increased 5%.
  • Earnings per share increased 50% to $1.23, and adjusted earnings per share increased 31% to $1.26.
  • Net income increased 52% to $83 million, and adjusted EBITDA increased 16% to $179 million.
  • Pharma segment delivered reported sales growth of 14% and core sales growth of 13% due to continued demand for proprietary drug delivery systems.

Headline financials

Total Revenue

$915M

Previous: $860M+6.4%
EPS

$1.23

Previous: $0.95+29.5%
Total Core Sales Growth

0.0%

Previous: 4.0%-100.0%
Pharma Core Sales Growth

13.0%

Previous: 7.0%+85.7%
Capital Expenditures

-$75.7M

Previous: -$77.8M+2.8%
Free Cash Flow

$7.44M

Previous: -$23.1M+132.3%
Net Income

$83.1M

Previous: $54.8M+51.7%
Operating Income

$112M

Previous: $83.9M+33.5%
Gross Profit

$915M

Previous: $860M+6.4%
Cash & Equivalents

$200M

Previous: $127M+57.6%
Total Assets

$4.44B

Previous: $4.3B+3.1%
Stock-Based Comp

$18.3M

Previous: $15M+21.5%

Revenue & EPS history

AptarGroup · Revenue · Quarterly

$915M

Q1 2024+6.4%vs Q1 2023
Beat estimate in 8 of 15 quarters(53%)
ActualEstimate

Revenue by segment

AptarGroup · $893M total across 3 segments · Q3 2023

  • Pharma
    $389M+13.3%
  • Beauty
    $324M-10.0%
  • Closures
    $180M+34.6%

Forward guidance

Aptar expects earnings per share for the second quarter of 2024 to be in the range of $1.30 to $1.38, excluding any restructuring expenses, changes in the fair value of equity investments and acquisition costs. This guidance is based on an effective tax rate range of 22% to 24%.

Tailwinds

  • Anticipate demand for proprietary drug delivery systems and elastomeric components for biologics to continue to grow in the second quarter.
  • Expect Pharma’s strong performance to continue throughout the year.
  • Expect demand to build for consumer dispensing technologies in the second quarter as destocking abates in North America.
  • Beauty will continue to focus on improving operational performance and ongoing cost management, including optimizing our footprint.
  • Closures will continue to focus on improving operational performance and ongoing cost management, including optimizing our footprint.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q1 2024

Historical avgQ1 2024

+0.3%

Avg return

Earnings day

-0.1%

Avg return

5 days after

+1.2%

Avg return

30 days after

63%

43 / 68 earnings

Positive

+9.2%

Q4 2017

Best reaction

-9.0%

Q3 2025

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-3.3%-0.8%-6.4%
Q4 2025+8.3%+12.9%+6.5%
Q3 2025-9.0%-7.1%+0.3%
Q1 2025+2.3%+2.1%+6.8%
Q4 2024-8.5%-9.4%-2.3%
Q3 2024+0.8%+0.6%+2.3%
Q2 2024+1.7%+1.1%+4.4%
Q1 2024+2.4%+3.1%+5.8%
Q4 2023+5.4%+3.1%+8.6%
Q3 2023+0.1%-0.9%+4.2%
Q2 2023+3.2%+2.1%+6.3%
Q1 2023+2.4%+4.1%-1.4%
Q4 2022+5.7%+4.2%+0.3%
Q3 2022+2.1%-1.9%+6.9%
Q2 2022+1.6%+0.5%-1.5%
Q1 2022+3.4%+2.5%-2.0%
Q4 2021+3.3%+3.8%+2.7%
Q3 2021-3.6%+1.7%+1.0%
Q2 2021-6.3%-6.6%-2.3%
Q1 2021-0.2%+2.6%-2.5%
Q4 2020-7.7%-10.4%-2.7%
Q3 2020+1.6%+6.4%+13.3%
Q2 2020-3.0%-0.2%-0.6%
Q1 2020-3.6%-4.1%+1.2%
Q4 2019-2.6%-7.0%-19.6%
Q3 2019-7.1%-8.9%-6.0%
Q2 2019-5.0%-5.4%-1.3%
Q1 2019+1.3%+2.3%+2.0%
Q4 2018+1.5%+0.0%+2.2%
Q3 2018+1.8%+2.1%+2.0%
Q2 2018+8.6%+8.1%+9.6%
Q1 2018+0.3%+0.4%+1.0%
Q4 2017+9.2%+11.8%+9.6%
Q3 2017-0.6%-1.6%-2.5%
Q2 2017-6.5%-6.3%-6.4%
Q1 2017+1.2%+1.1%+6.3%
Q4 2016+1.7%+0.4%+4.4%
Q3 2016-4.3%-7.4%-0.3%
Q2 2016-1.9%-3.9%-1.6%
Q1 2016-3.1%
Q4 2015-2.8%
Q3 2015+2.4%
Q2 2015+8.3%
Q1 2015+2.4%
Q4 2014+1.8%
Q3 2014+2.0%
Q2 2014-3.5%
Q1 2014-0.1%
Q4 2013+1.9%
Q3 2013+0.2%
Q2 2013-2.1%
Q1 2013-2.0%
Q4 2012-0.8%
Q3 2012-3.5%
Q2 2012+2.6%
Q1 2012+0.9%
Q4 2011+0.1%
Q3 2011+5.8%
Q2 2011-5.0%
Q1 2010+2.2%
Q1 2011+2.3%
Q4 2008+1.5%
Q4 2010+1.5%
Q3 2010+2.9%
Q3 2009+2.9%
Q4 2009+0.5%
Q2 2009+0.5%
Q2 2010+0.5%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro